Human medicines European public assessment report (EPAR): Cinryze, C1 inhibitor (human), Date of authorisation: 15/06/2011, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Phelinun, melphalan, Date of authorisation: 16/11/2020, Revision: 3, Status: Authorised

Medicinal products for human use: monthly figures - May 2025

Fourth European Medicines Agency and Affordable Medicines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, 1 July 2025

Human medicines European public assessment report (EPAR): Noxafil, posaconazole, Date of authorisation: 25/10/2005, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR): TachoSil, human fibrinogen,human thrombin, Date of authorisation: 08/06/2004, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Lumeblue (previously Methylthioninium chloride Cosmo), methylthioninium chloride, Date of authorisation: 19/08/2020, Revision: 5, Status: Authorised

Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence - Scientific guideline

Outcome of public consultation on the reflection paper use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes - Summary report of comments received during the public consultation and next steps